title: Half-antibody functionalized lipid-polymer hybrid nanoparticles for targeted drug delivery to carcinoembryonic antigen presenting pancreatic cancer cells.
abstract: Current chemotherapy regimens against pancreatic cancer are met with little success as poor tumor vascularization significantly limits the delivery of oncological drugs. High-dose targeted drug delivery, through which a drug delivery vehicle releases a large payload upon tumor localization, is thus a promising alternative strategy against this lethal disease. Herein, we synthesize anti-carcinoembryonic antigen (CEA) half-antibody conjugated lipid-polymer hybrid nanoparticles and characterize their ligand conjugation yields, physicochemical properties, and targeting ability against pancreatic cancer cells. Under the same drug loading, the half-antibody targeted nanoparticles show enhanced cancer killing effect compared to the corresponding nontargeted nanoparticles.
authors.affiliation: Department of Nanoengineering and Moores Cancer Center, University of California San Diego, La Jolla, California 92093, USA.
authors.forename: Che-Ming Jack
authors.initials: CM
authors.lastname: Hu
authors.forename: Sharmeela
authors.initials: S
authors.lastname: Kaushal
authors.forename: Hop S
authors.initials: HS
authors.lastname: Tran Cao
authors.forename: Santosh
authors.initials: S
authors.lastname: Aryal
authors.forename: Marta
authors.initials: M
authors.lastname: Sartor
authors.forename: Sadik
authors.initials: S
authors.lastname: Esener
authors.forename: Michael
authors.initials: M
authors.lastname: Bouvet
authors.forename: Liangfang
authors.initials: L
authors.lastname: Zhang
mesh_terms: D002272:Carcinoembryonic Antigen / Q000378:metabolism*; D002460:Cell Line; D002851:Chromatography, High Pressure Liquid; D016503:Drug Delivery Systems / Q000379:methods*; D006801:Humans; D008055:Lipids / Q000737:chemistry*; D053758:Nanoparticles / Q000737:chemistry*; D017239:Paclitaxel / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000378:metabolism*; D011108:Polymers / Q000737:chemistry*
chemical_list: D002272:Carcinoembryonic Antigen; D008055:Lipids; D011108:Polymers; D017239:Paclitaxel
references.citation: Bioconjug Chem. 1993 Sep-Oct;4(5):347-52
references.pmid: 8274518
references.citation: Small. 2006 Feb;2(2):209-15
references.pmid: 17193022
references.citation: J Immunol Methods. 2001 Jul 1;253(1-2):195-208
references.pmid: 11384681
references.citation: Science. 2009 Jun 12;324(5933):1457-61
references.pmid: 19460966
references.citation: CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49
references.pmid: 19474385
references.citation: Nat Nanotechnol. 2008 Mar;3(3):145-50
references.pmid: 18654486
references.citation: Cancer. 1973 Feb;31(2):324-7
references.pmid: 4687879
references.citation: Nature. 1979 Jun 21;279(5715):679-85
references.pmid: 221835
references.citation: Biomaterials. 2009 Mar;30(8):1627-34
references.pmid: 19111339
references.citation: ChemMedChem. 2007 Sep;2(9):1268-71
references.pmid: 17600796
references.citation: Anal Bioanal Chem. 2007 May;388(1):279-86
references.pmid: 17393156
references.citation: J Gastrointest Surg. 2008 Nov;12(11):1938-50
references.pmid: 18665430
references.citation: ACS Nano. 2008 Aug;2(8):1696-702
references.pmid: 19206374
references.citation: Bioconjug Chem. 2001 Mar-Apr;12(2):220-8
references.pmid: 11312683
references.citation: Nat Protoc. 2007;2(5):1152-65
references.pmid: 17546006
references.citation: Br J Cancer. 1998 Jul;78(2):181-8
references.pmid: 9683291
references.citation: FEBS Lett. 1997 Aug 11;413(1):177-80
references.pmid: 9287139
references.citation: Adv Drug Deliv Rev. 1999 Nov 10;40(1-2):103-127
references.pmid: 10837783
references.citation: Cancer. 2007 Aug 1;110(3):525-33
references.pmid: 17577216
references.citation: Cancer Chemother Pharmacol. 2009 Feb;63(3):529-33
references.pmid: 18766341